Breast Cancer Indication
Herceptin® therapy has now become a standard of care for HER2-overexpressing metastatic breast cancer, and a pharmDx™ test for HER2 protein overexpression or HER2 gene amplification is conducted to assess Herceptin® eligibility.
Leading pathologists endorse and use HercepTest™: See and hear why!
Dako Breast Cancer Literature
Dako provides a variety of material for HER2 testing in Breast Cancer.
Would you like further information? Please contact your local Dako representative for additional material.